StockNews.com initiated coverage on shares of MEI Pharma (NASDAQ:MEIP – Free Report) in a research report released on Sunday morning. The firm issued a buy rating on the stock.
MEI Pharma Stock Performance
Shares of NASDAQ:MEIP opened at $2.77 on Friday. The company has a 50 day moving average price of $2.86 and a 200 day moving average price of $3.00. The stock has a market capitalization of $18.45 million, a price-to-earnings ratio of -0.40 and a beta of 0.79. MEI Pharma has a 1-year low of $2.61 and a 1-year high of $6.91.
MEI Pharma (NASDAQ:MEIP – Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.20) earnings per share (EPS) for the quarter. On average, sell-side analysts expect that MEI Pharma will post -5.1 EPS for the current fiscal year.
Institutional Investors Weigh In On MEI Pharma
MEI Pharma Company Profile
MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.
Featured Articles
- Five stocks we like better than MEI Pharma
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- Profitably Trade Stocks at 52-Week Highs
- Netflix Is On Track To Hit $1,000 By Christmas
- Insider Selling Explained: Can it Inform Your Investing Choices?
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.